CONFIDENTIAL TREATMENT REQUESTED Portions of this exhibit indicated by “[***]” have been omitted, and such omitted portions have been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect...Stock and Asset Purchase and License Agreement • November 21st, 2013 • Akorn Inc • Pharmaceutical preparations • New York
THIS STOCK AND ASSET PURCHASE AND LICENSE AGREEMENT, is entered into as of November 15, 2013 (the “Effective Date”), by and among MERCK & CO, INC., a New Jersey corporation (“Merck & Co., Inc.”), MERCK SHARP & DOHME CORP., a New Jersey corporation (“MSD”, and together with Merck & Co., Inc., collectively, “Merck”), INSPIRE PHARMACEUTICALS, INC., a Delaware corporation (“Inspire”), and OAK PHARMACEUTICALS, INC., a Delaware corporation (“Buyer”).
ContractStock and Asset Purchase and License Agreement • May 5th, 2020 • New York
EX-2.1 2 a50756252ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 CONFIDENTIAL TREATMENT REQUESTED Portions of this exhibit indicated by “[***]” have been omitted, and such omitted portions have been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. STOCK AND ASSET PURCHASE AND LICENSE AGREEMENT Among MERCK & CO., INC., MERCK SHARP & DOHME CORP., INSPIRE PHARMACEUTICALS, INC., and OAK PHARMACEUTICALS, INC. November 15, 2013 CONFIDENTIAL TREATMENT REQUESTED Portions of this exhibit indicated by “[***]” have been omitted, and such omitted portions have been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. TABLE OF CONTENTS
